Future 1- or 2-degree Celsius increase in mean temperature expected to increase incidence of hyponatremia by 6.3 and 13.9 percent, respectively<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, March 15, 2022 (HealthDay News) — The incidence of hyponatremia hospitalizations is increased on the hottest days, with the greatest risk seen for women and the elderly, according to a study published online Feb. 22 in the Journal of Clinical Endocrinology & Metabolism<\/em>.<\/p>\n Buster Mannheimer, Ph.D., from the Karolinska Institutet in Stockholm, and colleagues examined the influence of ambient temperature on hyponatremia in the Swedish population. All patients hospitalized with a first-ever principal diagnosis of hyponatremia were identified between October 2005 and December 2014. The incidence rates of hyponatremia were calculated at a given temperature, in increments of 1 degree Celsius.<\/p>\n The researchers found that from \u00e2\u0088\u009210 to 10 degrees Celsius, the incidence of hyponatremia was stable at 0.3 per million person-days but increased rapidly at 24-hour mean temperatures greater than 15 degrees Celsius. At the highest recorded temperature, there were 1.96 hospitalizations per million person-days. The greatest risk was seen for women and the elderly; on the hottest days, the incidence was 30 hospitalizations per million person-days in individuals aged 80 years or older, corresponding to a 15-fold increase in incidence relative to cool days. An increase in the incidence of hyponatremia by 6.3 and 13.9 percent, respectively, is expected with a future increase of 1 or 2 degrees Celsius in mean temperature.<\/p>\n “We believe these estimates are quite conservative seeing as we didn t account for secondary diagnoses of hyponatremia, extreme weather events or an aging population,” a coauthor said in a statement. “Without adaptive measures, this suggests that over the next decades, rising global temperatures alone will increase the burden of hyponatremia on health care systems.”<\/p>\n Two authors disclosed financial ties to Otsuka Pharma Scandinavia; the study was funded by Cebix Incorporated.<\/p>\n